Neuren Pharmaceuticals Company Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.

The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.

In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Limited

Country	Australia
Industry	Biotechnology
Sector	Healthcare
CEO	Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.

Contact Details

Address: 697 Burke Road Camberwell, VIC 3124 Australia
Phone	61 3 9092 0480
Website	neurenpharma.com

Stock Details

Ticker Symbol	NEU
Exchange	Australian Securities Exchange
Fiscal Year	January - December
Reporting Currency	AUD
ISIN Number	NZNEUE0001S8

Key Executives

Name	Position
Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.	Chief Executive Officer, MD and Executive Director
Lauren Frazer C.A.	Chief Financial Officer and Company Secretary
Lawrence Glass BA (Biology)	Chief Science Officer
Gerry Zhao	Vice President of Corporate Development
Dr. Liza A. Squires M.D.	Chief Medical Officer